Early P1NP Suppression during Treatment of Low Bone Mass Postmenopausal Women with Risedronate 150 mg once-a Month
نویسندگان
چکیده
منابع مشابه
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, non...
متن کاملCIA-4080-Efficacy and safety of risedronate 150 mg once a month
Correspondence: Paula Rackoff Beth Israel Medical Center, 10 Union Square east, Suite 3D, New York, NY 10003, USA email [email protected] Abstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poo...
متن کامل[Efficacy of ibandronat 150 mg given once a month in the treatment of postmenopausal osteoporosis on the basis of biochemical bone markers--adhero study].
UNLABELLED INTRODUCTION. Menopausal osteoporosis is a disease of older age, and its development is related to the cessation of ovarian function together with a number of risk factors. Monthly dosing regimens are welcomed by women because of higher satisfaction and better adherence. This study was aimed at assessing the therapeutic effect of ibandronate given once a month to women with postmenop...
متن کاملOnce-monthly risedronate for postmenopausal osteoporosis
Bisphosphonates are the mainstay of treatment for postmenopausal women with osteoporosis. Despite numerous clinical trials documenting efficacy, tolerability, and safety of bisphosphonate therapy, long-term persistence and adherence to these agents remains low. This has serious consequences for patients with osteoporosis in that medication non-compliance is associated with significantly higher ...
متن کاملRisedronate treatment and extended fracture protection in postmenopausal women.
Sir, I would like to provide some perspective with regard to a published comment (1) on our study of risedronate treatment in postmenopausal women with vertebral fracture (2). The author suggests that risedronate is not effective in reducing vertebral fracture risk after the first year, and that the effects of risedronate "do not compare favorably" with those of alendronate and raloxifene. This...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Orthopedics and Rheumatology Open Access Journal
سال: 2017
ISSN: 2471-6804
DOI: 10.19080/oroaj.2017.08.555732